LinkedIn Profile

Access Xenon Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:xene 834648 Apr 14th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 272.00 Open Apr 13th, 2024 11:55PM Apr 13th, 2024 11:55PM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 13th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 273.00 Open Apr 12th, 2024 11:46PM Apr 13th, 2024 12:20PM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 12th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 273.00 Open Apr 11th, 2024 11:54PM Apr 12th, 2024 09:16AM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 11th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 274.00 Open Apr 11th, 2024 12:49AM Apr 11th, 2024 12:01PM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 10th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 274.00 Open Apr 9th, 2024 11:55PM Apr 10th, 2024 06:08PM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 9th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 274.00 Open Apr 9th, 2024 12:06AM Apr 9th, 2024 10:50AM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 8th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 274.00 Open Apr 8th, 2024 12:57AM Apr 8th, 2024 07:47PM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 7th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 274.00 Open Apr 7th, 2024 12:00AM Apr 7th, 2024 12:00AM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 6th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 274.00 Open Apr 6th, 2024 12:00AM Apr 6th, 2024 12:00AM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xene 834648 Apr 5th, 2024 12:00AM Xenon Pharmaceuticals Inc. 12K 274.00 Open Apr 5th, 2024 01:09AM Apr 5th, 2024 01:09AM Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our XEN1101 epilepsy program includes multiple Phase 3 clinical trials in patients with focal onset seizures and primary generalized tonic clonic seizures. In 2024, we are planning to initiate a Phase 3 XEN1101 program in major depressive disorder, based on topline data from our XEN1101 Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. Open drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels Open 3650 Gilmore Way Burnaby BC CA V5G 4W8 Xenon Pharmaceuticals Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.